Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Safety-Critical Software Put Under Scrutiny
Eliminating the potential for catastrophic medical, energy and transportation disasters due to software failure is the aim of a new $21-million global research centre to be located at McMaster University. It will be one of the first such centres in the world.

Type 1 Diabetes Cases In Children Under Five To Double By 2020
Cases of type 1 diabetes in children under five years across Europe will double by 2020 (from 2005 levels) if present trends continue. Numbers in children older than five will also increase substantially. The findings are discussed in an Article published Online First and in an upcoming edition of The Lancet, written by Dr Chris Patterson, Queen"s University, Belfast, UK, and Prof Gyula Soltç©sz, Pç©cs University, Pç©cs, Hungary, and colleagues.
News of the day
Sandra R. Gordon Wins Golden Trumpet Award From The Publicity Club Of Chicago
At the 50th Annual Trumpet Awards Luncheon at the Palmer House Hilton in Chicago, Sandra R. Gordon received one of the most coveted public relations awards from the Publicity Club of Chicago (PCC). As the director of public relations at the American Academy of Orthopaedic Surgeons (AAOS), Sandra was the lead visionary and creative force for their organization"s multi-faceted special event "Seventy-five Years of Orthopaedic Surgery".
Diagnostics

CHMP Recommends Expanded Use Of ISENTRESS(R) (raltegravir), From MSD, In Adult Patients With HIV-1 Infection

Merck, Sharp & Dohme (MSD) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending expanded marketing authorisation for ISENTRESS® (raltegravir) in combination with other antiretroviral (ARV) medicinal products for the treatment of HIV-1 infection in all appropriate adult patients, including patients starting HIV therapy for the first time (treatment-naç¯ve), as well as treatment-experienced patients. The positive opinion will be reviewed by the European Commission, which grants marketing authorisation to the 27 countries that are members of the European Union (EU), as well as Iceland and Norway. Raltegravir, the first and only approved integrase inhibitor, is currently approved in more than 80 countries across six continents for use in combination with other ARV agents for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing ARV therapy. The U.S. Food and Drug Administration recently approved an expanded indication for raltegravir in combination with other antiretroviral medicines for the treatment of HIV-1 infection in adult patients that includes patients starting HIV therapy for the first time, as well as treatment-experienced patients. In markets outside the United States, the use of raltegravir in treatment-naive patients is investigational and not currently licensed in this patient group. About Raltegravir Raltegravir works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit two other enzymes critical to the HIV-1 replication process "protease and reverse transcriptase" but raltegravir is the only drug approved that inhibits the integrase enzyme. Raltegravir is a single 400 mg tablet taken twice daily without regard to food. Raltegravir does not require boosting with ritonavir. Merck & Co., Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009